KAŇKOVÁ, Kateřina, Soňa ŠTĚPÁNKOVÁ, Lukáš PÁCAL, Marcela PONGRÁCOVÁ, Jan MUŽÍK a Jiří JARKOVSKÝ. Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study. In IDF 2009 Montreal. 2009.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study
Název česky Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study
Autoři KAŇKOVÁ, Kateřina, Soňa ŠTĚPÁNKOVÁ, Lukáš PÁCAL, Marcela PONGRÁCOVÁ, Jan MUŽÍK a Jiří JARKOVSKÝ.
Vydání IDF 2009 Montreal, 2009.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30202 Endocrinology and metabolism
Stát vydavatele Kanada
Utajení není předmětem státního či obchodního tajemství
Organizační jednotka Lékařská fakulta
Klíčová slova anglicky renin-angiotensin system
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: prof. MUDr. Kateřina Kaňková, Ph.D., učo 2524. Změněno: 19. 3. 2010 12:51.
Anotace
There are multiple determinants of progression of diabetic nephropathy (DN) such as metabolic and blood pressure control, albumin/proteinuria and genetics. One of the crucial pathogenic mechanisms is the over-activation of renin - angiotensin - aldosterone system (RAAS). We hypothesized that certain functional variants in the RAAS represent significant independent risk factors influencing the DN progression in subjects. Additionally, therapeutic benefit, predominantly based on the RAAS blockade - ACEIs and angiotensin receptor blockers (ARBs), might also be influenced by genetic variability within the RAAS components. Using clinical data collated during prospective follow-up of the cohort of diabetics with DN and advanced multivariate stat. methods we quantified the pathogenic contribution of main DN risk factors: (i) cumulative glycemia, blood pressure and proteinuria, (ii) other metabolic factors such as body weight and lipids in relation to the DN pharmacotherapy (i.e. cumulative received dose of ACEIs and ARBs and carrier state of selected candidate (pharmaco)genetic variants.
Anotace česky
There are multiple determinants of progression of diabetic nephropathy (DN) such as metabolic and blood pressure control, albumin/proteinuria and genetics. One of the crucial pathogenic mechanisms is the over-activation of renin - angiotensin - aldosterone system (RAAS). We hypothesized that certain functional variants in the RAAS represent significant independent risk factors influencing the DN progression in subjects. Additionally, therapeutic benefit, predominantly based on the RAAS blockade - ACEIs and angiotensin receptor blockers (ARBs), might also be influenced by genetic variability within the RAAS components. Using clinical data collated during prospective follow-up of the cohort of diabetics with DN and advanced multivariate stat. methods we quantified the pathogenic contribution of main DN risk factors: (i) cumulative glycemia, blood pressure and proteinuria, (ii) other metabolic factors such as body weight and lipids in relation to the DN pharmacotherapy (i.e. cumulative received dose of ACEIs and ARBs and carrier state of selected candidate (pharmaco)genetic variants.
Návaznosti
NR9443, projekt VaVNázev: Genetická variabilita enzymů pentózového cyklu jako faktor modulující nástup a progresi diabetické nefropatie
Investor: Ministerstvo zdravotnictví ČR, Genetická variabilita enzymů pentózového cyklu jako faktor modulující nástup a progresi diabetické nefropatie
VytisknoutZobrazeno: 25. 4. 2024 18:58